OLR1 and malignant colon neoplasm: 15-LOX-1 reexpression via Ad-15-LOX-1 in HCT116, HT29LMM, and LoVo colon cancer cells (Fig. 1A–D) markedly suppressed those cells' survival under hypoxia (inhibition ratios of cell survival of Ad-15-LOX-1 to Ad-luciferase: HCT116: 86.34 ± 2.32% (mean ± SD), HT29LMM: 60.08 ± 8.60%, LoVo: 93.18 ± 1.89%) (Fig. 1E–G).